Open AccessCisplatin‐induced nephrotoxicity and the protective effect of fosfomycin on it as demonstrated by using a crossover study of urinary metabolite levels
Author(s) -
Hayashi Masatoshi,
Numaguchi Masahide,
Watabe Hideki,
Enomoto Hideo,
Yaoi Yoshimasa
Publication year - 1997
Publication title -
acta obstetricia et gynecologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.401
H-Index - 102
eISSN - 1600-0412
pISSN - 0001-6349
DOI - 10.3109/00016349709024590
Subject(s) - medicine , nephrotoxicity , fosfomycin , urinary system , cisplatin , metabolite , crossover study , pharmacology , urology , chemotherapy , kidney , antibiotics , pathology , microbiology and biotechnology , biology , alternative medicine , placebo
Background. Cisplatin induces nephrotoxicity and this study evaluated the protective effect of fosfomycin on it in 11 gynecological cancer patients. Methods. The N‐acetyl‐β‐D‐glucosaminidase (NAG), β 2 ‐microglobulin (β 2 MG), creatinine (uCr) and total protein (TP) levels in a 24‐hour urine specimen as well as the blood urea nitrogen (BUN) and serum creatinine (sCr) were measured before and after CAPF chemotherapy alone (control) or with fosfomycin. Results. The results were statistically analyzed by using the t‐test. NAG, β 2 MG, uCr and TP levels increased significantly after chemotherapy in the control patients, but BUN and sCr levels did not change significantly. The NAG level in the control group was twice as high as in the fosfomycin group 8 days after chemotherapy (p<0.01). The uCr and TP in control patients increased significantly after chemotherapy when compared to those in patients coadministered fosfomycin. There were no significant changes in β 2 MG, BUN and sCr levels. Conclusions. Cisplatin affected the levels of NAG, β 2 MG, uCr and TP without influencing BUN and sCr levels. Fosfomycin, therefore, may be useful as a supplemental treatment for reducing cisplatin nephrotoxicity, especially proximal tubular damage.